Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01069133 · ClinicalTrials.gov registry record · Phase 1

Study of Rifaximin in Minimal Hepatic Encephalopathy

A Phase 1 study, sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target

NCT01069133 is a Phase 1 study that has completed, run by Hunter Holmes Mcguire Veteran Affairs Medical Center. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01069133, a Phase 1 study, has completed, sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

Rifaximin therapy will improve brain functioning on MRI scanning and change the microbiome and metabolome.

Interventions

  • DRUG Rifaximin
  • DRUG rifaximin

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2010-02
Est. Completion 2012-12
Phase Phase 1

What the Registry Record Tells You About NCT01069133

The ClinicalTrials.gov registry entry for NCT01069133 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hunter Holmes Mcguire Veteran Affairs Medical Center, which has 27 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Rifaximin is the first listed.

NCT01069133 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01069133 about?

NCT01069133 is a clinical study titled "Study of Rifaximin in Minimal Hepatic Encephalopathy". Rifaximin therapy will improve brain functioning on MRI scanning and change the microbiome and metabolome.

What is the current status of trial NCT01069133?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2010-02. Estimated completion is 2012-12.

What interventions are being tested in trial NCT01069133?

The interventions under investigation include: Rifaximin (DRUG), rifaximin (DRUG).

Who is sponsoring clinical trial NCT01069133?

This trial is sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center, which has 27 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.